Cyclic Immunofluorescent Imaging in Live Cells

Aperture Bio, Inc., Allston MA

Investigators

Abstract

PROJECT SUMMARY/ABSTRACT Cancer is a heterogeneous and dynamic disease that evolves throughout the course of treatment. Single-cell technologies have shown that the composition of tumors and the tumor microenvironment impact treatment efficacy. As such, it is challenging to predict which patients will optimally respond to current or next generation therapies (e.g. checkpoint inhibitors, cell therapies), and almost impossible to predict when or why a treatment will fail. To capture complex cellular functions and biological processes, methods need to be as dynamic as the cells they measure. The goal of this project is to determine the feasibility of using Aperture Bio’s platform for pre-clinical applications in drug development applications in organoids, as well as process development and research applications in cell therapy manufacturing, regenerative medicine, cell developmental biology, as well as oncology. The successful completion of this project will determine if Aperture Bio’s platform is suitable for the rigor required in these applications to improve current precision medicine development and delivery approaches. conjugation and quenching technologies can stain and quench live cells in multiple cellular compartments (e.g. membrane, cytosol, and nucleus) and quantify any cellular perturbations caused by multiplexed cycling.